[go: up one dir, main page]

FR2898497B1 - Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees - Google Patents

Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees

Info

Publication number
FR2898497B1
FR2898497B1 FR0602429A FR0602429A FR2898497B1 FR 2898497 B1 FR2898497 B1 FR 2898497B1 FR 0602429 A FR0602429 A FR 0602429A FR 0602429 A FR0602429 A FR 0602429A FR 2898497 B1 FR2898497 B1 FR 2898497B1
Authority
FR
France
Prior art keywords
apratastat
ynyloxy
thiomorpholin
benzenesulfonyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0602429A
Other languages
English (en)
Other versions
FR2898497A1 (fr
Inventor
Thibaud Biadatti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR0602429A priority Critical patent/FR2898497B1/fr
Priority to EP07731755A priority patent/EP1998779A2/fr
Priority to CA002645327A priority patent/CA2645327A1/fr
Priority to PCT/FR2007/050939 priority patent/WO2007107663A2/fr
Publication of FR2898497A1 publication Critical patent/FR2898497A1/fr
Application granted granted Critical
Publication of FR2898497B1 publication Critical patent/FR2898497B1/fr
Priority to US12/232,456 priority patent/US20090137569A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
FR0602429A 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees Expired - Fee Related FR2898497B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0602429A FR2898497B1 (fr) 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees
EP07731755A EP1998779A2 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-ý(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées
CA002645327A CA2645327A1 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxamide dans le traitement de pathologies inflammatoires cutanees
PCT/FR2007/050939 WO2007107663A2 (fr) 2006-03-20 2007-03-16 Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées
US12/232,456 US20090137569A1 (en) 2006-03-20 2008-09-17 Administration of (3S)-N-hydroxy-4-(sulfonyl)-2,2-dimethyl-3-thiomorpholine carboxamide or (S)-N_hydroxy-4-[4_(but-2-ynyloxy)phenylsulfonyl]-2,2-dimethyl thimomorpholine-3-carboxamide for preventing and/or treating inflammatory skin pathologies/afflictions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0602429A FR2898497B1 (fr) 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees

Publications (2)

Publication Number Publication Date
FR2898497A1 FR2898497A1 (fr) 2007-09-21
FR2898497B1 true FR2898497B1 (fr) 2008-05-16

Family

ID=37057052

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0602429A Expired - Fee Related FR2898497B1 (fr) 2006-03-20 2006-03-20 Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees

Country Status (5)

Country Link
US (1) US20090137569A1 (fr)
EP (1) EP1998779A2 (fr)
CA (1) CA2645327A1 (fr)
FR (1) FR2898497B1 (fr)
WO (1) WO2007107663A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012005229A1 (fr) 2010-07-08 2012-01-12 科研製薬株式会社 Dérivé de n-hydroxyformamide et produit pharmaceutique le contenant
GB2483499A (en) 2010-09-10 2012-03-14 S3 Res & Dev Ltd Diagnostics and Analysis of a Set Top Box
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594106A (en) * 1993-08-23 1997-01-14 Immunex Corporation Inhibitors of TNF-α secretion
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
AU2003284001A1 (en) * 2002-10-07 2004-05-04 Bristol-Myers Squibb Company Triazolone and triazolethione derivatives
GT200500139A (es) * 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos

Also Published As

Publication number Publication date
WO2007107663A3 (fr) 2007-11-22
FR2898497A1 (fr) 2007-09-21
WO2007107663A2 (fr) 2007-09-27
US20090137569A1 (en) 2009-05-28
CA2645327A1 (fr) 2007-09-27
EP1998779A2 (fr) 2008-12-10

Similar Documents

Publication Publication Date Title
EP1755584A4 (fr) Traitement de la myopie
EP2170360A4 (fr) Compositions de plantes pour le traitement du diabète et/ou de maladies associées à celui-ci
EP2217576A4 (fr) Composés benzodiazépinone utiles dans le traitement d'affections de la peau
EP1711191A4 (fr) Chlorite dans le traitement de maladie neurodegenerative
EP2063889A4 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
EP2020970A4 (fr) Traitement de l'oeil
EP1848431A4 (fr) Formulations liquides pour le traitement de maladies ou affections
EP1941908A4 (fr) Agent therapeutique pour maladie de coeur
EP1898930A4 (fr) Traitement d'etats inflammatoires
EP2043630A4 (fr) Dérivés de purine 6,9-disubstitués et leur utilisation pour le traitement de la peau
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
EP2185202A4 (fr) Utilisation de l'interleukine-22 dans le traitement de la stéatose hépatique
NO20081539L (no) Middel for behandling av betennelsestarmsykdom
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
EP2056858A4 (fr) Traitement de conditions de maladie pulmonaire
EP2134863A4 (fr) Modifications génétiques sur le chromosome 16 et procédés d'utilisation de celles-ci pour le diagnostic et le traitement du diabète de type i
EP1889058A4 (fr) Diagnostic et traitement de l'endométriose
EP1855679A4 (fr) Inhibiteurs de la beta-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
EP2220208A4 (fr) Utilisation du génotypage de l'haptoglobine dans le diagnostic et le traitement d'une maladie cardiovasculaire
EP1924717A4 (fr) Méthodes d'amélioration de la capacité de deshydratation de boue avec un traitement d'alpha-amylase
EP2398789A4 (fr) Inhibiteurs de bêta-sécrétase de type spiropyrrolidine pour le traitement de la maladie d'alzheimer
FR2919187B1 (fr) Utilisation d'ecorces de levure pour le traitement et/ou la prevention de l'hyperinsulinemie.
EP2152303A4 (fr) Antigènes de type chlamydia comme réactifs pour le diagnostic et le traitement d'infection et de maladie à chlamydia

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20161130